Glucose 30% Labesfal

Glucose 30% Labesfal is an intravenous solution containing 30% w/v glucose as the active ingredient. It is supplied as a sterile parenteral nutrition fluid intended for intravenous administration. The product is manufactured in the European Union and classified as a prescription‑only excipient/solvent used to provide an energy substrate and osmotic agent in clinical settings. It is supplied in glass bottles or containers and stored under conditions to maintain stability.

Glucose 30% Labesfal is used in clinical practice for several therapeutic purposes related to carbohydrate provision and fluid management.

- Management of hypoglycemia in patients unable to receive oral glucose. - Component of parenteral nutrition regimens to supply caloric energy. - Fluid and electrolyte replacement when combined with appropriate electrolytes. - Dilution of other intravenous medications requiring a glucose carrier. - Support during perioperative periods to maintain blood glucose levels.

Intravenous administration of a 30% glucose solution may be associated with a range of observed effects.

Common: - Transient increase in blood glucose levels shortly after infusion. - Mild irritation or pain at the catheter insertion site. - Shifts in serum electrolytes, most commonly a temporary decrease in potassium. - Nausea, mild abdominal discomfort, or a feeling of fullness.

Serious: - Marked hyperglycemia that may progress to osmotic diuresis and dehydration. - Fluid overload that can precipitate pulmonary edema, especially in patients with cardiac compromise. - Development of hyperosmolar hyperglycemic state in susceptible individuals. - Allergic reactions ranging from skin rash to anaphylactic shock.

When prescribing or administering Glucose 30% Labesfal, clinicians should consider several precautionary measures to ensure patient safety.

- Assess baseline blood glucose and electrolyte status before initiation. - Adjust infusion rate in patients with renal or cardiac insufficiency to avoid fluid overload. - Use compatible infusion sets and avoid mixing with incompatible drugs. - Monitor for signs of hyperglycemia, especially in diabetic patients. - Store the solution according to manufacturer guidelines and protect from light. - Discard any solution that appears discolored or contains particles. - Verify patient identity and prescription details to prevent medication errors.

Glucose 30% Labesfal can interact with other intravenous agents, influencing efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Simultaneous infusion of potassium chloride solutions, which may precipitate in high‑glucose concentrations. - Mixing with calcium‑containing solutions that can cause precipitation. - Use with certain antibiotics (e.g., aminoglycosides) that may have reduced stability in hypertonic glucose.

Use with caution: - Concurrent administration of diuretics that may exacerbate electrolyte disturbances. - Concurrent parenteral nutrition components requiring careful osmolarity balance. - Patients receiving corticosteroids, as they may increase glucose levels. - Blood transfusions, where hyperglycemia can affect red cell metabolism.